What does the future hold for cholesteryl ester transfer protein inhibition?

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Lipid Metabolism

Background:

• Genetic epidemiology studies clarify the relationship between lipoprotein levels and cardiovascular disease (CVD) risk.
• Apolipoprotein B-lipoproteins and triglycerides are confirmed as proatherogenic, while lipoprotein(a) is a significant CVD risk factor.
• The link between HDL cholesterol and CVD risk is complex; HDL cholesterol efflux capacity may be a more accurate predictor than HDL cholesterol levels alone.

Purpose of the Study:

• To review current research on cholesteryl ester transfer protein (CETP) inhibition and its impact on cardiovascular risk.
• To identify patient groups who may benefit from CETP inhibition therapy.
• To discuss the implications of recent genetic and clinical findings for CETP inhibition.

Main Methods:

• Review of recent genetic epidemiology studies on lipid levels and CVD risk.
• Analysis of findings from studies investigating HDL cholesterol efflux capacity.
• Examination of the effects of potent CETP inhibitors on lipoprotein profiles and HDL function.

Main Results:

• CETP inhibitors significantly reduce apolipoprotein B-containing lipoproteins and lipoprotein(a).
• These inhibitors increase HDL cholesterol levels and enhance HDL cholesterol efflux capacities.
• Recent studies suggest HDL cholesterol efflux capacity is a key predictor of cardiovascular risk, independent of HDL levels.

Conclusions:

• Two large phase 3 cardiovascular outcomes trials are evaluating the efficacy of CETP inhibition in high-risk populations.
• The future clinical application of CETP inhibition hinges on the results of these ongoing trials.
• Understanding the role of HDL cholesterol efflux is crucial for assessing the therapeutic potential of CETP inhibitors.